U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07785128) titled 'Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy' on Aug. 20.
Brief Summary: This study is testing whether a medicine called mycophenolate mofetil (MMF) works better than the usual treatment for people whose kidney disease, called IgA nephropathy, has not improved with standard care.
IgA nephropathy is a kidney disease that can cause protein to leak into the urine and, over time, can damage the kidneys. Some people with this disease do not get better even after standard treatment. Doctors call this "refractory" disease. Right now, there is no proven best treatment for these patients in Bangladesh.
This st...